title: Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment.
abstract: The first choice of treatment for American cutaneous leishmaniasis is the pentavalent antimonial drug. Although it has been shown that this treatment is mostly effective and indicated, some disadvantages should be taken into account such as side effects, long term treatment inconveniences and counter-indication for patients suffering from cardiopathy, nephropathy; yet, aging, pregnancy and other conditions. With the advent of the vaccine anti-American cutaneous leishmaniasis as a prophylactic measure, studies on therapy using the vaccine associated or not with other drugs have been performed by many investigators and it is currently among the alternative treatments and prevention measures for American cutaneous leishmaniasis. In conclusion, the association between antimony and vaccine (immunochemotherapy) showed the same cure rate when compared with the standard treatment (100%) and it was also able to reduce the salt volume in 17.9% and treatment length from 87 to 62 days, decreasing side effects.
authors.affiliation: Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. wilsonmayrink@uol.com.br
authors.forename: Wilson
authors.initials: W
authors.lastname: Mayrink
authors.forename: Ana Cristina de Carvalho
authors.initials: AC
authors.lastname: Botelho
authors.forename: Paulo Araújo
authors.initials: PA
authors.lastname: Magalhães
authors.forename: Sebastião Mariano
authors.initials: SM
authors.lastname: Batista
authors.forename: Antonio de Oliveira
authors.initials: Ade O
authors.lastname: Lima
authors.forename: Odair
authors.initials: O
authors.lastname: Genaro
authors.forename: Carlos Alberto da
authors.initials: CA
authors.lastname: Costa
authors.forename: Maria Norma de
authors.initials: MN
authors.lastname: Melo
authors.forename: Marilene Susan Marques
authors.initials: MS
authors.lastname: Michalick
authors.forename: Paul
authors.initials: P
authors.lastname: Williams
authors.forename: Magno
authors.initials: M
authors.lastname: Dias
authors.forename: Waleska Teixeira
authors.initials: WT
authors.lastname: Caiaffa
authors.forename: Evaldo do
authors.initials: Ed
authors.lastname: Nascimento
authors.forename: George Luiz Lins
authors.initials: GL
authors.lastname: Machado-Coelho
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007891:Leishmania / Q000276:immunology; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000628:therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage; D016052:Protozoan Vaccines / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D001500:BCG Vaccine; D009942:Organometallic Compounds; D016052:Protozoan Vaccines; D008536:Meglumine; D000077485:Meglumine Antimoniate